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ABSTRACT	
Objectives:	To	summarise	and	compare	the	benefits	and	harms	of	biological	agents	used	as	
monotherapy	for	rheumatoid	arthritis	(RA).	
Methods:	We	searched	MEDLINE,	EMBASE,	the	Cochrane	Central	Register	of	Controlled	Trials	and	
other	sources	for	randomised	trials	that	compared	biological	monotherapy	with	methotrexate,	
placebo,	or	other	biological	monotherapies.	Primary	outcomes	were	American	College	of	
Rheumatology	50%	improvement	(ACR50)	and	the	number	of	patients	who	discontinued	due	to	
adverse	events.	Our	network	meta-analysis	was	based	on	mixed-effects	logistic	regression,	
including	both	direct	and	indirect	comparisons	of	the	treatment	effects,	whilst	preserving	the	
randomised	comparisons	within	each	trial.	
Results:	The	analysis	comprises	28	trials	(8,602	patients),	including	all	nine	biological	agents	
approved	for	RA.	Of	the	included	trials,	8	(29%)	included	‘DMARD-naïve’,	and	20	(71%)	‘DMARD-
Inadequate	responder’	(DMARD-IR)	patients.	All	agents	except	anakinra	and	infliximab	were	
superior	to	placebo	with	regard	to	ACR50.	Etanercept	and	rituximab	were	superior	to	anakinra.	
Tocilizumab	was	superior	to	adalimumab,	anakinra,	certolizumab,	and	golimumab.	When	including	
only	DMARD-IR	trials,	the	same	statistical	pattern	emerged,	complemented	with	superiority	of	
etanercept	and	tocilizumab	compared	with	abatacept.	Focusing	on	recommended	doses,	both	
etanercept	and	tocilizumab	were	superior	to	adalimumab	and	certolizumab.	No	differences	in	
benefit	among	etanercept,	tocilizumab,	and	rituximab	were	found.	However,	because	rituximab	
was	evaluated	in	just	40	patients,	our	confidence	in	the	estimates	is	limited,	No	statistically	
significant	differences	among	biological	agents	were	found	with	respect	to	harm.	
Conclusions:	Evidence	suggests	etanercept	or	tocilizumab	to	be	the	most	appropriate	choice	for	
RA	patients	treated	with	biological	monotherapy.
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INTRODUCTION	
Inflammation	in	rheumatoid	arthritis	(RA)	patients	should	be	suppressed	as	early	as	possible	
{Emery,	2006	1954	/id},	with	pharmacologic	treatment	directed	at	tight	control	of	inflammation	
{Huizinga,	2010	2381	/id;Smolen,	2010	2327	/id}.	Disease-modifying	antirheumatic	drugs	
(DMARDs)	can	interfere	with	the	disease	process	{Smolen,	2014	1918	/id;Singh,	2012	2330	/id}.	
Conventional	synthetic	DMARDs	(csDMARDs)	include	methotrexate	(MTX),	hydroxychloroquine,	
leflunomide,	sulfasalazine,	and	glucocorticoids.	csDMARDs	can	also	be	used	in	various	
combinations	{Singh,	2012	2330	/id}.	MTX	is	considered	the	standard	csDMARD,	but	in	high-risk	
patients,	early	combination	of	MTX	with	prednisolone	or	a	biological	agent	improves	outcomes	
{Klarenbeek,	2010	2382	/id}.	
Biological	agents	are	usually	given	to	patients	with	active	RA	who	have	not	achieved	
satisfactory	response	to	one	or	more	csDMARDs	such	as	MTX	{Smolen,	2014	1918	/id}.	Currently,	
the	biological	agents	approved	for	RA	include	the	following	nine	drugs:	five	tumour	necrosis	factor	
inhibitors	(TNFi)	–	adalimumab,	certolizumab	pegol,	etanercept,	golimumab,	and	infliximab;	and	
four	with	other	modes	of	action	–	anakinra,	abatacept,	rituximab,	and	tocilizumab	{Furst,	2012	
2331	/id}.	Infliximab	and	golimumab	are	approved	by	the	U.S.	Food	and	Drug	Administration	(FDA)	
and	the	European	Medicines	Agency	(EMA)	only	with	concomitant	use	of	MTX,	and	rituximab	only	
with	a	csDMARD	{Emery,	2013	2499	/id}.	All	other	biological	agents	are	also	approved	in	
monotherapy,	albeit	abatacept	and	anakinra	only	by	the	FDA	{Emery,	2013	2499	/id}.		
Recently,	concerns	have	been	raised	as	to	whether	external	factors,	including	lack	of	
adherence	to	csDMARD	therapy,	might	reduce	the	anticipated	benefit	associated	with	use	of	
biologic	agents	if	patients	discontinue	use	of	a	concomitant	csDMARD.	Evidence	from	real-life	
registry	data	shows	that	approximately	one-third	of	RA	patients	treated	with	biological	agents	use	
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them	as	monotherapy	and	that	when	MTX	is	prescribed	in	combination	with	a	biological	agent,	
more	than	half	of	the	patients	do	not	take	MTX	as	prescribed	{Emery,	2013	2499	/id}.	
As	most	biological	agents	have	shown	more	favourable	results	in	combination	with	
csDMARD	therapy	{Singh,	2009	1746	/id},	and	many	RA	patients	might	not	adhere	to	their	MTX	
prescription,	it	is	important	to	evaluate	the	benefit	and	harm	associated	with	use	of	biological	
agents	as	monotherapy,	and	not	only	the	traditional	combination	therapy	strategies	{Bergman,	
2010	1744	/id;Guyot,	2011	2376	/id;Guyot,	2012	2375	/id}.	Therefore,	the	objective	of	this	study	
was	to	assess	the	efficacy	and	safety	of	the	individual	biological	agents	applied	as	monotherapy	in	
patients	with	RA	to	inform	decision	makers	on	the	relative	effectiveness	of	biological	agents	used	
in	monotherapy.	
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METHODS	
A	network	meta-analysis	of	randomised	trials	combined	direct	and	indirect	evidence.	Methods	of	
analysis	and	inclusion	criteria	were	specified	in	advance	and	documented	in	a	protocol	(PROSPERO	
2012:CRD42012002800).	Both	protocol	and	analyses	were	prepared	according	to	the	
‘Methodological	Expectations	for	Cochrane	Intervention	Reviews’	(MECIR)	program.	Our	study	
conforms	to	the	PRISMA	guidelines	for	reporting	systematic	reviews	{Liberati,	2009	2163	/id}.	
	
Literature	search	
We	searched	The	Cochrane	Central	Register	of	Controlled	Trials,	Medline,	Embase,	and	
ClinicalTrials.gov	for	published	reports	from	inception	of	each	database	through	December	16,	
2014	(Supplement	Table	1).	We	combined	terms	for	rheumatoid	arthritis	with	the	nine	biological	
agents	of	interest	(abatacept,	adalimumab,	anakinra,	certolizumab	pegol,	etanercept,	golimumab,	
infliximab,	rituximab,	and	tocilizumab).	Search	results	were	limited	to	randomised	controlled	trials	
(RCTs)	by	applying	appropriate	filters.	We	then	collated	additional	reports	identified	in	relevant	
systematic	reviews	not	retrieved	through	the	electronic	databases.	We	also	scrutinized	relevant	
reports	on	FDA's	and	EMA's	websites	and	searched	relevant	pharmaceutical	companies’	websites	
to	identify	unpublished	trial	data.	
	
Trial	selection	
Double-blind	randomised	trials	studying	the	administration	of	one	of	the	eligible	biological	agents	
were	considered	eligible	if	they	were	used	as	monotherapy	in	an	(FDA/EMA)-approved	route	of	
administration	in	RA	patients.	Trials	were	considered	eligible	if	at	least	one	within-study	
comparison	was	available	with	placebo,	MTX,	or	another	approved	biological	agent	as	
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monotherapy.	We	did	not	include	open	label	trials,	trials	with	no	full	English	text	available,	trials	
not	reporting	ACR50	responses,	trials	comparing	the	same	biological	agent	with	and	without	MTX,	
or	trials	comparing	different	doses	of	the	same	biological	agent	in	monotherapy.	
	
Outcome	measures	
The	core-outcome	data	in	each	study	consist	of	the	sample	size	of	the	groups	and	the	number	of	
patients	in	each	group	who	met	the	predefined	outcomes	of	interest.	A	priori	it	was	decided	to	use	
the	outcome	assessment	at	6	months,	if	available.	If	6	months	data	were	unavailable,	we	used	
data	closest	to	6	months	in	each	trial.	Two	major	outcomes	were	considered	co-primary	
{Ghogomu,	2014	2462	/id}:	benefit	–	defined	as	the	ACR50	response	criteria	{Chung,	2006	1641	
/id};	and	harm	by	proxy	–	determined	by	the	number	of	withdrawals	because	of	adverse	events	
{Ioannidis,	2004	1372	/id}.	ACR50	is	considered	a	validated,	clinically	meaningful	binary	measure	
of	benefit	{Singh,	2009	1746	/id}.	Withdrawals	that	occur	because	of	adverse	events	are	a	measure	
of	patients’	tolerance	of	adverse	events	reported	consistently	{Singh,	2009	1746	/id}.	The	
secondary	outcomes	were	ACR20,	ACR70,	total	number	of	patients	who	withdrew	from	the	study,	
and	the	number	of	patients	who	experienced	at	least	one	serious	adverse	event	(SAE).	
	
Data	collection	and	risk-of-bias	assessment	
Outcome	measure	extractions	were	based	on	the	intention-to-treat	(ITT)	population	whenever	
possible.	Two	independent	reviewers	(ST	and	AD)	extracted	all	the	data.	Data	were	collected	on	
the	general	characteristics	of	the	RCT	and	sample	size.	The	interventions	being	compared	were	
extracted,	including	dosages	and	frequency	of	the	administered	drugs.	
The	internal	validity	of	the	included	studies	was	evaluated	on	the	basis	of	the	
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apparent	risk	of	bias	within	each	RCT;	domains	(including	selection	bias,	performance	bias,	
detection	bias,	attrition	bias,	and	reporting	bias)	were	assessed	using	the	items	of	the	risk-of-bias	
tool	as	recommended	by	the	Cochrane	Collaboration	{Higgins,	2011	1853	/id}.	
	
Data	synthesis	and	analysis	
We	used	random	effects	meta-analyses	by	default,	assuming	the	true	treatment	effect	differs	
from	study	to	study	{Riley,	2011	2502	/id}.	Unlike	a	contrast-based	(standard)	meta-analysis	
approach	{DerSimonian,	1986	525	/id},	an	arm-based	approach	was	used	to	include	multiple	
comparisons	in	the	network	meta-analysis	{Salanti,	2008	2039	/id}	in	order	to	combine	both	direct	
and	indirect	comparisons.	We	performed	mixed-effects	logistic	regression	using	an	(arm-based)	
random	effects	model	within	an	empirical	Bayes	framework	{Singh,	2009	1746	/id;	Platt,	1999	
2711	/id}.	The	generalised	linear	mixed	model	(GLMM)	incorporates	a	vector	of	random	effects	
and	a	design	matrix	for	the	random	effects	{Platt,	1999	2711	/id}.	Allowance	was	made	for	
differences	in	heterogeneity	of	effects	between	different	drugs	by	specifying	that	the	linear	
predictor	varies	at	the	level	of	study	and	as	an	interaction	between	study	and	drug.	In	the	network	
meta-analyses,	we	measured	heterogeneity	(i.e.,	between-study	variance)	for	the	analysis	using	T2	
(an	estimate	for	Tau-squared),	which	examines	heterogeneity	because	of	Study	and	Study×Drug	
interaction	(smaller	values	indicate	a	better	model	per	se).	
	
Sensitivity	analyses		
Post	hoc	sensitivity	analyses	on	the	primary	outcomes	were	conducted	to	explore	impact	of	
csDMARD	history	and	dose:	(i)	exclusion	of	studies	not	evaluating	csDMARD	inadequate	responder	
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patients;	(ii)	exclusion	of	trial	arms	not	evaluating	an	FDA-	or	EMA-recommended	average	
maintenance	dose	(defined	in	Supplement	Table	2),	including	MTX	comparator	trial	arms	not	
evaluating	an	oral	MTX	dose	of	at	least	10	mg	weekly	(or	subcutaneous	in	equivalent	dose).	If	only	
one	trial	arm	evaluated	a	recommended	dose,	the	whole	study	was	excluded	from	the	sensitivity	
analysis	(placebo	trial	arms	[i.e.,	no	biological	or	csDMARD	treatment]	were	categorised	as	
recommended	dose	for	technical	reasons).	
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-	Figure	1.	(Flow	diagram)	Around	Here	-	
	
RESULTS	
Characteristics	of	reviewed	studies	
Searches	of	four	primary	electronic	databases	and	reviews	identified	4,405	unique	references.	Of	
the	total,	818	proved	potentially	relevant	for	full-text	review,	and	45	references	that	reported	28	
unique	randomised	trials	of	all	9	FDA/EMA	approved	biological	agents	proved	eligible	(Figure	1).	
The	28	randomised	trials,	comprising	a	total	of	79	unique	trial-arms,	included	8,602	
patients	with	RA:	abatacept	(2	trials;	350	patients),	adalimumab	(6	trials;	1,928	patients),	anakinra	
(1	trial;	472	patients),	certolizumab	(2	trials;	421	patients),	etanercept	(5	trials;	2,047	patients),	
golimumab	(4	trials;	1,279	patients),	infliximab	(1	trial;	58	patients),	rituximab	(1	trial;	80	patients),	
and	tocilizumab	(6	trials;	1,967	patients).	The	included	trials	had	different	study	designs:	13	
compared	a	biological	agent	in	monotherapy	with	placebo;	14	compared	a	biological	agent	in	
monotherapy	to	MTX;	and	only	one	study	compared	two	biological	agents	(tocilizumab	in	
monotherapy	vs.	adalimumab	in	monotherapy)	{Gabay,	2013	2418	/id}	(Table	1).	The	network	of	
eligible	comparisons	for	the	primary	efficacy	outcome	(ACR50)	is	shown	in	Figure	2.	The	network	
for	withdrawals	because	of	adverse	events	was	essentially	the	same.	Of	the	28	included	trials,	8	
(29%)	included	‘csDMARD-naïve’,	20	(71%)	‘csDMARD-IR’,	and	0	(0%)	enrolled	biological	agent	
inadequate	responder	patients	(Table	1;	references	available	in	Supplement	Table	3).		
	
-	Figure	2.	(Network	diagram)	Around	Here	-	
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Benefit	and	harm	according	to	primary	outcomes	
As	illustrated	in	Figure	3A,	most	biological	agents	(as	well	as	MTX)	were	statistically	significantly	
more	likely	than	placebo	to	lead	to	an	ACR50	response;	exceptions	were	anakinra	and	infliximab.	
Of	the	28	included	studies	(all	reporting	ACR50),	24	reported	withdrawals	because	of	adverse	
events.	Compared	to	placebo,	withdrawals	because	of	adverse	events	were	not	statistically	
significantly	higher	among	patients	for	any	of	the	drugs	(Figure	3B).	For	sensitivity,	direct	pairwise	
meta-analyses	were	conducted	for	both	primary	benefit	and	harm	outcome.	As	presented	in	
Supplement	Figure	1-4,	estimates	from	the	network	meta-analysis	were	in	agreement	with	the	
direct	evidence	(i.e.,	point	estimate	from	the	network	meta-analysis	were	included	within	the	
95%CI	of	the	direct	estimate).	The	only	exception	was	tocilizumab	compared	with	placebo	for	
withdrawal	because	of	adverse	events,	where	the	point	estimate	from	the	network	meta-analysis	
(1.84)	was	not	included	within	the	95%CI	of	the	direct	estimate	(0.04	to	1.29).	Further,	for	benefit	
the	direct	pairwise	meta-analysis	found	relevant	inconsistency	for	certolizumab	pegol	compared	
with	placebo	(I2=71%),	with	no	obvious	explanation.	Relevant	inconsistency	was	also	found	for	
etanercept	and	tocilizumab	compared	with	MTX	(I2=83%	and	80%	respectively),	probably	
explained	by	the	low	MTX	dose	(8	mg	weekly)	used	in	two	Japanese	trials	(etanercept	{Takeuchi,	
2012};	tocilizumab	{Nishimoto,	2009}.	These	two	trials	were	excluded	in	the	sensitivity	analysis	of	
recommended	dose.	For	harm,	relevant	inconsistency	was	also	found	for	etanercept	compared	
with	MTX	(I2=79%),	probably	explained	be	the	low	MTX	dose	applied	in	the	Japanese	trial.	
	
-	Figure	3A&B.	(Network	meta-analysis	forest	plots	of	primary	benefit/harm	each	
biological	agent	compared	with	placebo)	Around	Here	
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Figure	4	presents	all	comparisons	among	the	nine	biological	agents	in	monotherapy,	MTX,	and	
placebo	in	terms	of	both	benefit	(ACR50)	and	harm	(withdrawals	because	of	adverse	events).	
Etanercept	was	more	likely	to	lead	to	clinical	response	than	anakinra	(OR=3.38;	95%	CI,	1.26	to	
9.01)	and	MTX	(1.54;	1.03	to	2.32;	Figure	4).	Rituximab	also	appears	more	effective	than	anakinra	
(4.26;	1.01	to	17.86).	Tocilizumab	appears	superior	when	compared	with	each	of	the	following:	
adalimumab	(1.97;	1.22	to	3.17),	anakinra	(3.97;	1.49	to	10.53),	certolizumab	pegol	(2.35;	1.06	to	
5.24),	golimumab	(1.77;	1.00	to	3.13),	and	MTX	(1.82;	1.23	to	2.68).	All	other	comparisons	among	
biological	agents	in	monotherapy	were	not	statistically	significantly	different.	When	harms	were	
monitored	by	proxy	according	to	all	comparisons	(Figure	4),	none	of	the	drugs	included	in	the	
network	appeared	more	likely	than	others	to	lead	to	discontinuation	due	to	adverse	events.	
	
Figure	4.	(Primary	Benefit	and	harm	of	all	biological	agents	according	to	the	
network	meta-analysis)	Around	Here	
	
Benefit	and	harm	according	to	secondary	outcomes	
From	the	primary	analysis,	based	on	the	primary	benefit-outcome,	statistical	evidence	suggested	
etanercept	to	be	more	efficacious	than	anakinra	and	MTX.	In	secondary	outcome	analyses,	this	
finding	was	supported	for	ACR20	but	not	for	ACR70,	where	etanercept	was	not	statistically	
significantly	different	from	MTX	(1.47;	0.92	to	2.36)	(Supplement	Table	4).	Rituximab	was	
statistically	significantly	superior	to	anakinra	for	the	primary	benefit-outcome,	which	was	
supported	by	analyses	of	ACR20	and	ACR70.	Tocilizumab	was	statistically	superior	to	adalimumab,	
anakinra,	certolizumab	pegol,	golimumab,	and	MTX	for	ACR50,	an	effect	that	appeared	robust	
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when	ACR20	and	ACR70	rates	were	evaluated	(Supplement	Table	4)	with	one	exception;	
tocilizumab	was	not	statistically	significantly	superior	to	golimumab	(1.85;	0.97	to	3.52).	
When	secondary	harm	measures,	SAEs,	and	the	total	number	of	withdrawals	
(Supplement	Table	5)	were	examined,	no	statistically	significant	differences	occurred	for	SAEs	
(anakinra	was	not	included	due	to	lack	of	reporting).	For	the	total	number	of	withdrawals,	
tocilizumab	was	statistically	significantly	more	favourable	than	abatacept,	adalimumab,	anakinra,	
and	MTX.	
	
Sensitivity	analyses	in	trials	using	the	recommended	dose	
When	the	analysis	of	the	primary	benefit	outcome	(ACR50)	was	based	on	treatment	with	the	
recommended	maintenance	dose	(Supplement	Table	6),	anakinra	and	infliximab	were	not	
included,	as	these	biological	agents	were	not	evaluated	at	the	recommended	doses.	The	apparent	
superiority	of	etanercept	over	MTX	could	not	be	confirmed	statistically	for	its	recommended	dose	
(OR= 1.25;	0.90	to	1.72).	However,	in	its	recommended	dose,	etanercept	was	now	more	likely	to	
lead	to	clinical	response	than	adalimumab	and	certolizumab	pegol.	The	findings	for	tocilizumab	
appeared	robust,	with	superiority	over	adalimumab,	certolizumab	pegol,	and	MTX.	However,	the	
apparent	superiority	of	tocilizumab	over	golimumab	could	not	statistically	be	confirmed	for	
recommended	dose	(OR= 2.07;	0.89	to	4.85).	Monitoring	harms	by	proxy	according	to	all	
comparisons	(Supplement	Table	6),	adalimumab,	etanercept,	tocilizumab	at	their	recommended	
doses,	and	MTX	(≥10	mg	weekly)	were	all	more	likely	than	placebo	to	lead	to	discontinuation	due	
to	adverse	events.	However,	no	differences	among	any	biological	agents	or	MTX	were	statistically	
significant.	
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Sensitivity	analyses	among	DMARD-IR	patients	
When	the	analysis	of	the	primary	benefit	outcome	(ACR50)	was	based	on	studies	of	patients	who	
had	had	an	inadequate	response	to	csDMARDs	(DMARD-IR;	see	Supplement	Table	7),	the	findings	
for	etanercept	were	robust	as	it	was	still	more	likely	to	lead	to	clinical	response	than	anakinra	and	
MTX.	The	apparent	superiority	of	rituximab	over	anakinra	could	not	be	statistically	confirmed	
(3.03;	0.66	to	14.29).	Also,	the	findings	for	tocilizumab	appeared	robust,	with	superiority	over	
adalimumab,	anakinra,	golimumab,	and	MTX.	However,	the	apparent	superiority	of	tocilizumab	
over	certolizumab	pegol	could	not	be	confirmed	in	the	sensitivity	analysis	based	on	DMARD-IR	
patients	only	(2.18;	0.89	to	5.32).	
	 Further,	to	explore	how	much	impact	the	only	“biologics	head-to-head”	comparison	study	
(ADACTA)	{Gabay,	2013	2418	/id}	had	on	the	estimates	in	the	network,	the	DMARD-IR	sensitivity	
analyses	were	performed	with	exclusion	of	the	ADACTA	study	on	tocilizumab	against	adalimumab	
in	DMARD-IR	patients	(Supplementary	Table	8),	revealing	sparse	data	supporting	superiority	of	
tocilizumab	compared	with	other	biological	agents	prior	to	the	ADACTA	study	(e.g.,	vs.	
adalimumab	1.81;	0.80	to	4.15).	In	the	ADACTA	study,	tocilizumab	was	statistically	significantly	
superior	to	adalimumab	(2.33;	1.47	to	3.69).	
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DISCUSSION	
This	study	suggests	there	are	differences	in	effectiveness	but	not	in	harm	among	biological	agents	
applied	as	monotherapy	in	RA.	Patient-important	benefits	such	as	ACR50	occurred	more	
frequently	with	etanercept	or	tocilizumab	monotherapy	than	with	other	biological	agents.	
Although	tocilizumab	was	superior	to	a	higher	number	of	agents	than	the	number	etanercept	was	
superior	to,	no	statistically	significant	difference	between	tocilizumab	and	etanercept	was	found	
throughout	the	conducted	analyses.	Further,	in	recommended	dose,	both	etanercept	and	
tocilizumab	were	superior	to	adalimumab	and	certolizumab	pegol.	Despite	rituximab's	being	
superior	to	anakinra,	had	response	rates	comparable	to	etanercept	and	tocilizumab	against	
placebo,	and	no	differences	between	rituximab	and	etanercept	or	tocilizumab	were	found,	
evidence	on	rituximab	was	based	on	one	study	only,	where	40	patients	were	treated	with	
rituximab	monotherapy,	thereby	limiting	our	confidence	in	these	findings.	
Our	findings	are	relevant	because	substantial	numbers	of	patients	either	do	not	
tolerate	MTX	(or	other	csDMARDs),	or	discontinue	these	agents	for	unknown	reasons	{Emery,	
2013	2499	/id}.	Registry	data	confirm	that	biological	monotherapy	is	a	common	treatment	in	RA	
{Yazici,	2008	4353	/id;Jorgensen,	2015	4352	/id;Emery,	2013	2499	/id}.	In	the	sensitivity	analysis	of	
csDMARD-inadequate	responder	patients,	most	agents	had	response	rates	comparable	to	
continued	use	of	MTX	monotherapy,	where	only	etanercept	and	tocilizumab	monotherapy	were	
superior	to	MTX.	
Only	one	head-to-head	trial	comparing	monotherapy	with	two	biological	agents,	
tocilizumab	and	adalimumab,	has	been	published	{Gabay,	2013	2418	/id}.	We	therefore	
performed	a	network	meta-analysis	to	indirectly	compare	other	evaluated	therapies,	cognisant	of	
the	limitations	of	this	approach	{Mills,	2012}.	This	methodology	relies	upon	assumptions	about	the	
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similarities	of	the	included	trials	in	terms	of	comparability	of	patient	and	study	characteristics	
{saliati	2014}.	However,	the	comparative	effectiveness	paradigm	dictates	that	guideline	panels	as	
well	as	clinicians	and	patients	are	challenged	with	the	dilemma	of	choosing	among	these	therapies	
in	the	absence	of	robust	comparative	data	about	their	relative	benefit	and	harm	differences.	
Other	(recent)	network	meta-analyses,	to	a	large	extent,	support	our	findings	regarding	
etanercept’s	and	tocilizumab’s	favourable	profiles	in	terms	of	ACR50	{Buckley,	2015	4355	
/id;Migliore,	2015	4356	/id;Orme,	2012	4357	/id}.	However,	due	to	different	study	
inclusion/exclusion	criteria	and	different	methodological	approaches,	these	studies	differ	with	
respect	to	the	comparative	effectiveness	between	etanercept	and	tocilizumab.	In	the	study	by	
Buckley	et	al.	{Buckley,	2015	4355	/id},	tocilizumab	monotherapy	was	not	statistically	significantly	
different	from	TNFi	monotherapy	(i.e.,	all	TNFi’s	were	combined).	Migliore	et	al.	{Migliore,	2015	
4356	/id},	who	restricted	their	eligibility	criteria	to	studies	of	biological	agents	approved	in	EU	for	
RA	as	monotherapy;	found	that	tocilizumab	was	superior	to	etanercept.	Other	discrepancies	when	
compared	to	our	study	included	the	minimum	treatment	duration	of	16	weeks,	the	date	of	search,	
and	omission	of	unpublished	trials	(e.g.,	the	now	published	FUNCTION	study	[tocilizumab	
monotherapy	vs.	MTX]{Burmester	2015}	had	results	available	online	April	2013	in	the	company	
trial	database).	Although	Migliore	et	al.	was	limited	to	double-blind	RCTs,	as	was	our	study,	it	
included	the	open-label	SAMURAI	study	(tocilizumab	monotherapy	vs.	csDMARDs;	only x-ray	
reader-blinded).	Further,	the	adalimumab	monotherapy	study	CHANGE	{Miyasaka,	2008}	and	the	
etanercept	monotherapy	study	by	Takeuchi	et	al.	{Takeuchi	2012}	were	not	included,	although	
both	fulfilled	inclusion	criteria	and	were	published	before	date	of	search	(September	2013).	The	
third	network	meta-analysis	by	Orme	et	al.	{Orme,	2012	4357/id}	showed	tocilizumab	
monotherapy	was	not	statistically	significantly	different	from	etanercept	monotherapy.	
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Our	evidence	synthesis	also	has	limitations.	The	included	studies	span	a	17-year	period,	
from	1998	through	2015;	so	patients	enrolled	in	early	studies	may	differ	from	those	included	in	
more	recent	studies.	Moreover,	the	RA	patients	enrolled	in	the	different	monotherapy	studies	are	
to	some	extent	heterogeneous	(encompassing	different	duration	of	diseases	and	differences	in	the	
extent	of	prior	MTX	failure).	Further,	only	one	head-to-head	trial	was	identified,	reducing	our	
confidence	in	the	comparative	estimates.	In	other	words,	future	biological	agent	monotherapy	
head-to-head	trials	will	likely	have	an	important	impact	on	our	estimates.	A	priori,	we	defined	a	
hierarchical	list	of	outcomes,	giving	priority	to	6	months	data	when	available.	When	they	were	not	
available,	other	time	points	were	used	(e.g.,	nine	studies	lasted	only	16	weeks	or	less,	and	in	six	
studies	safety	data	were	available	only	after	one	year	or	more.	Comparisons	among	studies	across	
different	time	points	could	potentially	limit	the	interpretation	of	our	results.	Further,	whether	our	
results	can	be	extrapolated	to	long-term	efficacy	and	safety	is	not	clear.	
In	conclusion,	trial	evidence	suggests	etanercept	or	tocilizumab	to	be	the	most	appropriate	
choice	to	RA	patients	treated	with	biological	monotherapy.	
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